Valeant Pharmaceuticals International, the parent company of Bausch & Lomb, has reported a sales decline of 11.1 percent to $2.1 billion in the first quarter of 2017 as compared to the first quarter of 2016. However, sales in the Bausch & Lomb's International segment rose by about $4 million to $1.15 billion in the quarter. On a constant currency basis, the sales increase in this segment was of 4 percent, driven by increases in volumes especially in Europe, the Middle East, South Africa, Asia and Australia, partially offset by declines in the U.S.